^
    Back
    Association details:
    Biomarker:PDGFRA D842V
    Cancer:Gastric Cancer
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    In patients with the D842V mutation, adjuvant therapy with imatinib is not recommended and mutational testing is highly relevant to avoid overtreatment of GISTs with imatinib in this setting.
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    J Clin Oncol
    Title:

    PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

    Excerpt:
    Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K). However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y. Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive. 
    DOI:
    10.1200/JCO.2005.14.068